Jul 15, 2025 07:01AM Acumen Pharmaceuticals partners with JCR for alzheimer's drug development

Jun 17, 2025 05:16AM Citi Starts Acumen Pharmaceuticals, Inc. (ABOS) at Buy

May 13, 2025 06:00PM Acumen Pharmaceuticals, Inc. (ABOS) Tops Q1 EPS by 3c

Apr 2, 2025 07:00AM Acumen Pharmaceuticals, Inc (ABOS) Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

Mar 31, 2025 06:40AM Acumen Pharmaceuticals, Inc. (ABOS) PT Lowered to $11 at H.C. Wainwright

Mar 26, 2025 08:05AM Acumen Pharmaceuticals (ABOS) Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

Mar 19, 2025 08:00AM Acumen Pharmaceuticals (ABOS) Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers

Nov 12, 2024 04:24PM Acumen Pharmaceuticals, Inc. (ABOS) Misses Q3 EPS by 14c

Nov 6, 2024 08:01AM Acumen Pharmaceuticals, Inc (ABOS) Appoints Amy Schacterle as Chief Regulatory Officer & Head of Quality

Oct 23, 2024 08:02AM Acumen Pharmaceuticals (ABOS) to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease

Oct 4, 2024 07:05AM Stifel Reiterates Buy Rating on Acumen Pharmaceuticals, Inc. (ABOS)

Oct 3, 2024 06:58AM H.C. Wainwright Reiterates Buy Rating on Acumen Pharmaceuticals, Inc. (ABOS)

Sep 26, 2024 08:02AM Acumen Pharmaceuticals (ABOS) Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease

Aug 14, 2024 06:12AM BTIG Reiterates Buy Rating on Acumen Pharmaceuticals, Inc. (ABOS)

Aug 13, 2024 07:22AM Acumen Pharmaceuticals, Inc. (ABOS) Misses Q2 EPS by 7c

Jul 25, 2024 04:10PM Citi Starts Acumen Pharmaceuticals, Inc. (ABOS) at Buy, 'Targeting Amyloid Beta Oligomers as a Differentiated Strategy in Alzheimer’s'

Jun 10, 2024 05:09AM BTIG Reiterates Buy Rating on Acumen Pharmaceuticals, Inc. (ABOS)